Reception at the Polpharma stand at CPHI 2017 in Frankfurt (24-26.10.2017). © BIOCOM/Oliver Schnell

The world’s largest event for pharma professionals, CPHI worldwide, will see an expansion to the rapidly-growing field of biologics next year in Madrid

© Ayoxxa

AYOXXA’s LUNARIS platform:?In a case study "Translational proteomics: a new perspective for
ophthalmology research, Ayoxxa gives insights into the capabilities of its Lunaris multiplex protein
analysis platform.

© IDA Ireland

US biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (€85m) expansion plan for the company’s campus there.

© Adbar/Wikimedia Commons

Portuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.

3D rendering of a  T lymphocyte. © Blausen.com staff (2014).

French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition. 

© Uniqure

Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.

Sébastien Stoitzner, CEO. © Gensearch

Today, there are greater expectations among healthcare providers for engagement with life sciences companies to be digital. For life sciences companies, there is significant potential to leverage digital technologies to reach more HCPs.

Overview of study results: Green - high erformance/low risk; yellow - medium performance/medium risk; red - low performance/high risk. (© nova-institute, Cologne)

A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EU’s climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.

Simple schematic of an ADC. © ADC Therapeutics Sarl

Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors  include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.

John Brennan, Boris Mannhardt and MEP Frank Bogovi? in Brussels. Picture © BIOCOM

European Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bio­economy, industry association Europa­Bio celebrated the European Biotech Week with an exhibition, Discovering European Biotech Innovation, in the European Parliament in Brussels.